^
    1d
    Analysis of ten cases of Acute lymphoblastic leukemia with non-KMT2A::AFF1 transcriptional variant 11q23 rearrangements (PubMed, Zhonghua Yi Xue Yi Chuan Xue Za Zhi)
    The 11q23 rearrangement ALL with non-KMT2A::AFF1 transcript is mainly KMT2A::MLLT1, T-ALL is more common, and the rate of chromosomal karyotype detection is relatively low. Persistent positive KMT2A-r is unfavorable for patient survival, and allo-HSCT during the CR1 period may improve patient survival.
    Retrospective data • Journal • IO biomarker
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule) • CD8 (cluster of differentiation 8) • KMT2A (Lysine Methyltransferase 2A) • CD38 (CD38 Molecule) • WT1 (WT1 Transcription Factor) • CD22 (CD22 Molecule) • AFF1 (AF4/FMR2 Family Member 1) • CD34 (CD34 molecule) • CD5 (CD5 Molecule) • MME (Membrane Metalloendopeptidase) • CD7 (CD7 Molecule) • MLLT3 (MLLT3 Super Elongation Complex Subunit) • CD2 (CD2 Molecule) • AFDN (Afadin, Adherens Junction Formation Factor) • FUT4 (Fucosyltransferase 4) • MLLT10 (MLLT10 Histone Lysine Methyltransferase DOT1L Cofactor)
    |
    KMT2A rearrangement
    1d
    Clinical analysis of 7 cases of childhood acute lymphoblastic leukemia with PDGFRB rearrangement (PubMed, Zhongguo Dang Dai Er Ke Za Zhi)
    PDGFRB-rearranged ALL in children is uncommon, is most often detected in B-ALL, and presents at a relatively older age. Fusion partners are diverse and frequently co-occur with additional gene mutations. Despite high initial remission, MRD negativity and molecular clearance rates remain suboptimal, and allogeneic hematopoietic stem cell transplantation may improve prognosis.
    Retrospective data • Journal
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RUNX1 (RUNX Family Transcription Factor 1) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • ETV6 (ETS Variant Transcription Factor 6) • IKZF1 (IKAROS Family Zinc Finger 1) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • PAX5 (Paired Box 5) • EBF1 (EBF Transcription Factor 1) • CCDC88C (Coiled-Coil Domain Containing 88C) • SSBP2 (Single Stranded DNA Binding Protein 2) • TAL1 (TAL BHLH Transcription Factor 1)
    |
    RET rearrangement
    3d
    Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant (clinicaltrials.gov)
    P1, N=30, Suspended, University of Chicago | Recruiting --> Suspended
    Trial suspension
    |
    melphalan • fludarabine IV
    6d
    PAMD-Ch17, a Polymeric Analog of Plerixafor, Induces Mitochondrial Dysfunction in T-ALL Cells Independent of CXCR4. (PubMed, Mol Cancer Ther)
    Collectively, our results indicate that PAMD-Ch17 has anti-leukemic effects against T-ALL cells but not healthy cells, likely mediated through a CXCR4 independent, mitochondrial based mechanism. These findings support further development of PAMDs as potential therapeutics for patients with T-ALL.
    Journal
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4)
    |
    plerixafor
    8d
    MB-CART19.1 in Relapsed/Refractory Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P=N/A, N=12, Recruiting, King Hussein Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD19 (CD19 Molecule)
    |
    zorpocabtagene autoleucel (MB-CART 19.1)
    14d
    TET2 germline mutation in a patient with sequential lymphoid malignancies: a novel case report. (PubMed, Ann Hematol)
    This represents the first documented case of the sequential transformation across three distinct lymphoid malignancies attributable to a germline TET2 mutation, underscoring its pivotal role in lymphomagenesis and clonal evolution. The online version contains supplementary material available at 10.1007/s00277-026-06930-4.
    Journal
    |
    TET2 (Tet Methylcytosine Dioxygenase 2)
    |
    TET2 mutation
    14d
    Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL Patients (clinicaltrials.gov)
    P2, N=28, Recruiting, The First Affiliated Hospital of Soochow University | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Venclexta (venetoclax) • azacitidine
    14d
    U69-CART-Cells For R/R T-ALL (clinicaltrials.gov)
    P1, N=12, Recruiting, The First Affiliated Hospital of Soochow University | Initiation date: Dec 2025 --> Jun 2026 | Trial primary completion date: Jul 2026 --> Dec 2026
    Trial initiation date • Trial primary completion date
    15d
    OC-01-23002: Long-term Follow-up study for relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LL) patients previously treated with OC-1 cells. (2024-516617-20-00)
    P2/3, N=20, Recruiting, Onechain Immunotherapeutics S.L. | Not yet recruiting --> Recruiting
    Enrollment open
    16d
    Efficacy and Safety of CD7 CAR-T in Newly Diagnosed High-Risk T-LBL/ALL (clinicaltrials.gov)
    P1, N=10, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New P1 trial
    17d
    Case Report: Ataxia telangiectasia with severe hemorrhagic cystitis. (PubMed, Front Pediatr)
    AT patients may be at risk for delayed, potentially life-threatening hemorrhagic cystitis, particularly following cyclophosphamide exposure. Cystoscopy is essential for diagnosis and enables timely endoscopic management.
    Journal
    |
    ATM (ATM serine/threonine kinase)
    |
    cyclophosphamide
    18d
    UMG1 Defines a Targetable Subset of T-Cell Lymphomas and Enables Precision Immunotherapy With a First-in-Class CD3ε Bispecific Engager. (PubMed, Hematol Oncol)
    Our findings suggest that the UMG1/CD3ε-BTCE selectively exerts potent anti-tumor activity against a relevant subset of TCLs. These findings support the development of a precision immunotherapy approach for patients with UMG1-expressing aggressive hematologic malignancies.
    Journal • IO biomarker
    |
    ALK (Anaplastic lymphoma kinase) • SPN (Sialophorin)
    |
    ALK negative
    |
    Zolinza (vorinostat)